An observational study in Cerebral Hemorrhage, Subarachnoid Hemorrhage and Ischemic Stroke, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-19.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Cerebral Hemorrhage with a site in France — 11 open to participants now, 11 under way, 2 of them phase 3. Cerebral Hemorrhage · France.
Among the 24 studies in Cerebral Hemorrhage with a site in France, this one is the 8th largest by planned enrollment of the 11 observational ones that give a count, is the only one that started in 2023, is one of 11 observational ones, reaches primary completion later than 0 of the 10 other live ones, and was the 15th registered.
458 studies on the registry are indexed under Cerebral Hemorrhage; 173 are open to participants now.
Browse Cerebral Hemorrhage studies →11 of the 24 studies in Cerebral Hemorrhage with a site in France are open now. Recruiting first, the newest first:
University Hospital, Tours · Sites in France
Ages 18+
University Hospital, Lille · Sites in France
Ages 18–65 · Healthy volunteers
Centre Hospitalier Universitaire de Nīmes · Sites in France
Ages 18+
University Hospital, Tours · Sites in France
Ages 18+
University Hospital, Lille · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 115 Cerebral Hemorrhage studies recruiting now, 61 (53%) set no upper age limit and 9 (8%) stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 1990; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 300 across 181 observational studies indexed under Cerebral Hemorrhage.
Median enrollment 300 across the 13 interventional studies, 455 across the 11 observational. Of the 13 that completed or were terminated, 1 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 24 have an industry lead sponsor. The 10 most frequent:
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
Assistance Publique - Hôpitaux de Paris has 3 studies filed under Cerebral Hemorrhage — fewer than ten, so there is no comparison to draw.
2 of the studies in Cerebral Hemorrhage with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06781034Centre Hospitalier Universitaire de NīmesDescriptive Study on MRI Contrast of Acute Cerebral Hemorrhage in Different Microangiopathies | 2026-12 |
| NCT06802588University Hospital, ToursOptimization of the Management of Non-Traumatic Intracerebral Hemorrhage (OPT-ICH) | 2027-05-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 24 studies in Cerebral Hemorrhage with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of the study is to assess brain tissue perfusion by contrast-enhanced ultrasound perfusion imaging (PerCEUS) in acute brain injuries. More precisely, it aims :
The main aim is to evaluate the heterogeneity of brain perfusion, thus diagnosing brain tissue hypoperfusion with PerCEUS, then to correlate it with the usual multimodal monitoring.
Earlier after hospitalization in neurointensive care, when the study physician needs to realize a contrast ultrasound imaging and without delaying any emergency procedure, a PerCEUS will be performed in patients with an acute brain injury. After acquisition, data from PerCEUS will be transferred to an external evaluation unit and analysed offline, using commercially available software Qlab (Philips ®). According to the localization of acute brain injuries with magnetic resonance imaging (MRI) and/or computed tomography (CT), several regions-of-interest (ROI, at least three in each area) will be chosen :
Every parameters of multimodal monitoring used at the moment of PerCEUS will be relieved :
The actual PerCEUS measurement takes place at the bedside, is performed by the study physician, and takes about 5 minutes.
The trial duration per patient is 30 minutes, ending after 25 minutes of oversight
Patients hospitalized in neurosurgical intensive care in Lariboisière Hospital, Paris, with acute brain injuries
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contrast-enhanced ultrasound perfusion imaging (PerCEUS)
Diagnostic Test: Measuring contrast-enhanced ultrasound perfusion with phase inversion harmonic imaging
Contrast-enhanced ultrasound perfusion imaging (PerCEUS) will be performed by a dedicated study team. The transcranial color duplex sonography will be performed with a 1-5 MHz dynamic sector array (S5-1) from a Philips Epiq 7 ultrasound machine (Philips Healthcare, Andover, MA). The field-of-view will be set to an imaging depth of 150 mm in a sector angle of 90°. The imaging plane will be then tilted to the diencephalic, in which the frontal horns of the side ventricles and the third ventricle serve as landmarks and where the anterior and posterior middle cerebral artery (MCA) territory and the basal ganglia (BG) as region of interest could be identified without artefacts from major vessels. High mechanical index bolus imaging will be performed from the sanest side of the head. Data acquisition of 45 seconds will be recorded immediately after the beginning of the contrast ultrasound imaging, using a mechanical index (MI) setting of 1.1 and a frame rate of 33 Hz.
Evaluation of the heterogeneity of brain perfusion by time-to-peak (TPI) measurement
Comparison between time-to-peak (TPI) intensities measured in ROIs in each area by PerCEUS
Time frame: 30 minutes after PerCEUS
Evaluation of the heterogeneity of brain perfusion by peak-intensities (PI) measurement
Comparison between peak-intensities (PI) measured in ROIs in each area by PerCEUS
Time frame: 30 minutes after PerCEUS
Correlation between PerCEUS parameters and cerebral perfusion as assessed by ICP and MAP
Correlations test between TPI/PI and ICP/CPP/MAP
Time frame: 30 minutes after PerCEUS
Correlation between PerCEUS parameters and cerebral perfusion as assessed by TCD
Correlations test between TPI/PI and MFV
Time frame: 30 minutes after PerCEUS
Correlation between PerCEUS parameters and cerebral perfusion as assessed by NIRS
orrelations test between TPI/PI and rSO2
Time frame: 30 minutes after PerCEUS
Correlation between PerCEUS parameters and cerebral perfusion as assessed by SjvO2
Correlations test between TPI/PI and SjvO2
Time frame: 30 minutes after PerCEUS
Plan to share: No
Started Jul 2023 (actual). Primary completion is estimated for Jul 2025, 24 months after the start.
Of 88 non-industry observational studies under Cerebral Hemorrhage, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 179. This study's planned 24 months is below that.
Counting every sponsor, half of 90 studies reached it within 62 months; a quarter within 27 and three quarters within 179.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →